Is entecavir ideal for the treatment of lamivudine-refractory chronic hepatitis B?

Hepatology

Volumn 48, Issue 5, 2008, Pages 1726-1727

  Su, Chien Wei ^a,b   Wu, Jaw Ching ^a,b   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; EMTRICITABINE; ENTECAVIR; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; TENOFOVIR; VIRUS DNA; DRUG DERIVATIVE; GUANINE;

DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENE MUTATION; GENOTYPE; HEPATITIS B; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; BLOOD; METABOLISM; NOTE; RETREATMENT; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DNA, VIRAL; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; RETREATMENT; TREATMENT OUTCOME;

EID: 56149112943     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22520     Document Type: Letter

References (8)

1. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. HEPATOLOGY 2008;48:99-108.
2. Lok ASF, McMahon BJ. AASLD practice guidelines: Chronic hepatitis B. HEPATOLOGY 2007;45:507-539.
3. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. HEPATOLOGY 2006;44:1656-1665.
4. Carosi G, Rizzetto M. Treatment of chronic hepatitis B: Recommendations from an Italian workshop. Dig Liver Dis 2008;40:603-617.
5. Hsu CW, Yeh CT, Chang ML, Liaw YF. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology 2007;132:543-550.
6. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok ASF. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008;48:391-398.
7. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlostsky JM, et al. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. HEPATOLOGY 2007;46: 254-265.
8. Keefee EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-897.